Galicia Launches €805M Biotechnology Strategy to Drive Innovation and Competitiveness (2026–2030)

The Galician government has approved the new “Biotechnology Strategy for Galicia 2026–2030,” a plan designed to mobilize €805 million over the next five years in order to strengthen the sector’s competitiveness and position it alongside Europe’s leading bioregions.

The strategy, developed collaboratively by the Galician Innovation Agency and the Life Sciences Business Technology Cluster (Bioga), outlines a projected €572 million in public investment alongside the attraction of €233 million in private capital. This roadmap will shape the regional government’s R&D&I policies through five key areas of focus, including scientific excellence, the data ecosystem, and biointelligence.

Galicia has been selected to host one of the 19 artificial intelligence hubs designated by the European Commission

As part of a broader strategic redefinition of the biotechnology ecosystem, the Xunta de Galicia has identified four priority sectors for targeted action, reflecting current market specialization trends. Among these, the health and pharmaceutical subsector stands out as a central pillar of the initiative.

This focus builds on the convergence of knowledge, infrastructure, and capabilities that the region has developed over the past decade. Institutional efforts in this domain will concentrate on advancing biomedical innovation and implementing precision medicine. In parallel, the plan also emphasizes the agri-food and food technology sectors, particularly through the development of functional foods aimed at improving health and supporting active aging.

The application of new technologies in healthcare will represent another major priority throughout the strategy’s implementation period. Galicia has been selected to host one of the 19 artificial intelligence hubs designated by the European Commission. This infrastructure, known as 1HealthAI, is expected to begin recruiting its first professionals soon, with the objective of becoming fully operational by 2028. The hub will integrate advanced computing capabilities with biotechnology to address healthcare challenges using a comprehensive approach that links human, animal, and environmental health.

The integration of health data is identified as a key strategic opportunity within the document, particularly through the convergence of artificial intelligence, advanced data processing, and biomedicine. The 1HealthAI complex is intended to act as a central driving force, enabling the application of supercomputing across Galicia’s biotechnology subsectors.

The regional government anticipates that this infrastructure will accelerate the adoption of intelligent solutions among biotechnology companies, research institutions, and the healthcare system, ultimately positioning Galicia as a leading European hub for biotechnology and health data integration.

To support the strategy’s objectives, the sector will benefit, for the first time, from a dedicated call for proposals focused exclusively on this innovation ecosystem. Scheduled for launch next autumn, this funding program will finance biotechnology R&D projects while promoting collaboration between small and medium-sized enterprises and other stakeholders.

Additionally, the strategy includes the creation of a specialized business accelerator, Business Factory, which will operate through the Galician Institute for Economic Promotion.

__

(Featured image by Max Kukurudziak via Unsplash)

DISCLAIMER: This article was written by a third party contributor and does not reflect the opinion of Born2Invest, its management, staff or its associates. Please review our disclaimer for more information.

This article may include forward-looking statements. These forward-looking statements generally are identified by the words “believe,” “project,” “estimate,” “become,” “plan,” “will,” and similar expressions. These forward-looking statements involve known and unknown risks as well as uncertainties, including those discussed in the following cautionary statements and elsewhere in this article and on this site. Although the Company may believe that its expectations are based on reasonable assumptions, the actual results that the Company may achieve may differ materially from any forward-looking statements, which reflect the opinions of the management of the Company only as of the date hereof. Additionally, please make sure to read these important disclosures.

First published in diariofarma. A third-party contributor translated and adapted the article from the original. In case of discrepancy, the original will prevail.

Although we made reasonable efforts to provide accurate translations, some parts may be incorrect. Born2Invest assumes no responsibility for errors, omissions or ambiguities in the translations provided on this website. Any person or entity relying on translated content does so at their own risk. Born2Invest is not responsible for losses caused by such reliance on the accuracy or reliability of translated information. If you wish to report an error or inaccuracy in the translation, we encourage you to contact us.